ALX Oncology Holdings Inc ALXO.OQ ALXO.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 45 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $2.50, about 79.3% above its last closing price of $0.52
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.45
-0.46
-0.58
Missed
-25
Dec. 31 2025
-0.62
-0.67
-0.55
Beat
17.9
Sep. 30 2024
-0.78
-0.78
-0.58
Beat
25.6
Jun. 30 2024
-0.77
-0.77
-0.76
Beat
1.7
Mar. 31 2024
-0.85
-0.84
-0.71
Beat
15.1
Dec. 31 2023
-0.81
-0.84
-0.93
Missed
-10.5
Sep. 30 2023
-0.82
-0.87
-1.24
Missed
-42.5
Jun. 30 2023
-0.88
-0.88
-0.84
Beat
4.5
This summary was machine generated August 4 at 20:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)